Caplin Point Laboratories Ltd

Caplin Point Lab Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Caplin Point Laboratories Ltd

₹ 1,490 -0.51%
22 Jul 4:01 p.m.
caplinpoint.net BSE: 524742 NSE: CAPLIPOINT
About

Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.[1]

Key Points

Product Portfolio[1]
Presently, the company has a very wide portfolio of pharma products with 4,000+ registered products, 650+ formulations and presence in 36 therapeutic segments. It has minimal reliance for revenues on a single product/ therapeutic segment.

Website BSE NSE
  • Market Cap ₹ 11,306 Cr.
  • Current Price ₹ 1,490
  • High / Low ₹ 1,619 / 839
  • Stock P/E 24.7
  • Book Value ₹ 305
  • Dividend Yield 0.30 %
  • ROCE 26.5 %
  • ROE 23.0 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 21.1% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 24.7%
  • Company's median sales growth is 23.0% of last 10 years

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
279 300 304 326 339 346 359 372 389 395 410 436 453
193 208 202 225 239 244 253 263 265 269 273 293 308
Operating Profit 86 93 101 101 100 102 106 109 124 127 137 142 145
OPM % 31% 31% 33% 31% 29% 30% 29% 29% 32% 32% 34% 33% 32%
9 9 8 10 12 14 16 14 11 12 21 17 17
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 10 12 12 12 11 11 11 11 11 11 12 14 16
Profit before tax 85 90 98 99 100 105 110 112 124 127 146 145 146
Tax % 20% 20% 21% 20% 19% 18% 17% 13% 18% 18% 20% 18% 17%
68 72 77 79 81 86 92 97 101 104 116 120 121
EPS in Rs 8.77 9.37 9.91 9.89 10.43 11.21 12.09 12.84 13.45 13.62 15.13 15.43 16.01
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Jun 2013 Jun 2014 Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
127 173 252 239 402 540 649 863 1,061 1,269 1,467 1,694
105 137 192 175 276 345 417 603 732 874 1,025 1,143
Operating Profit 22 36 60 64 125 195 232 260 329 395 442 551
OPM % 18% 21% 24% 27% 31% 36% 36% 30% 31% 31% 30% 33%
2 4 3 4 10 13 19 41 23 38 55 67
Interest 1 1 1 0 1 1 1 0 2 1 1 1
Depreciation 2 4 8 7 13 19 23 32 37 47 45 53
Profit before tax 22 36 53 60 121 188 227 269 314 386 451 564
Tax % 37% 27% 23% 24% 21% 23% 22% 20% 20% 20% 16% 18%
14 26 41 46 96 145 177 215 251 308 377 461
EPS in Rs 1.85 3.42 5.43 6.05 12.65 19.15 23.35 28.42 32.03 39.56 49.57 60.19
Dividend Payout % 27% 23% 18% 20% 12% 10% 9% 9% 9% 10% 9% 4%
Compounded Sales Growth
10 Years: 30%
5 Years: 21%
3 Years: 17%
TTM: 16%
Compounded Profit Growth
10 Years: 42%
5 Years: 21%
3 Years: 24%
TTM: 22%
Stock Price CAGR
10 Years: 37%
5 Years: 31%
3 Years: 23%
1 Year: 73%
Return on Equity
10 Years: 28%
5 Years: 25%
3 Years: 25%
Last Year: 23%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Jun 2013 Jun 2014 Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 15 15 15 15 15 15 15 15 15 15 15 15
Reserves 28 47 78 113 210 349 582 858 954 1,252 1,649 2,301
5 3 2 2 1 1 36 113 235 219 222 2
87 115 134 137 133 136 109 139 159 250 305 380
Total Liabilities 135 180 229 267 358 500 743 1,126 1,364 1,736 2,191 2,697
33 102 113 144 152 169 227 272 305 287 280 453
CWIP 51 25 31 0 3 15 10 20 14 18 221 117
Investments 1 0 0 0 17 47 70 61 11 89 230 376
50 52 85 122 186 269 436 772 1,033 1,343 1,461 1,752
Total Assets 135 180 229 267 358 500 743 1,126 1,364 1,736 2,191 2,697

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Jun 2013 Jun 2014 Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
32 60 50 42 68 66 83 45 269 337 271 318
-45 -44 -23 -6 -36 -69 -100 -54 -30 -377 -216 -313
-1 -6 -9 -14 -7 -12 90 80 -24 -41 -28 -38
Net Cash Flow -15 10 19 23 25 -14 73 70 215 -81 27 -32

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Jun 2013 Jun 2014 Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 2 0 8 12 30 85 90 97 96 91 98 117
Inventory Days 45 35 37 57 44 44 47 210 139 149 159 183
Days Payable 111 112 112 168 155 144 76 57 68 102 90 106
Cash Conversion Cycle -63 -77 -67 -99 -81 -16 61 251 166 138 166 194
Working Capital Days -176 -181 -128 -114 -29 47 104 167 152 166 159 218
ROCE % 52% 64% 68% 62% 68% 63% 45% 33% 28% 28% 26% 27%

Shareholding Pattern

Numbers in percentages

Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
69.03% 68.91% 68.89% 68.88% 68.88% 68.80% 70.66% 70.63% 70.62% 70.62% 70.62% 70.56%
1.76% 2.11% 2.07% 2.03% 2.15% 2.24% 2.36% 2.68% 3.09% 2.84% 3.33% 3.38%
1.19% 1.22% 1.25% 1.12% 1.12% 1.12% 0.64% 0.27% 0.21% 0.43% 1.08% 1.49%
28.02% 27.76% 27.78% 27.97% 27.85% 27.84% 26.33% 26.44% 26.08% 26.11% 24.95% 24.59%
No. of Shareholders 83,46285,57783,82984,86884,53882,68782,14678,95678,06879,43881,40980,411

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls